MODELING AND SIMULATION (M&S) SUPPORT ELTROMBOPAG (EPAG) DOSAGE ESCALATION BASED ON PLATELET COUNT FOR PEDIATRIC PATIENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (CITP)

被引:0
|
作者
Grainger, J. [1 ]
Sirachainan, N. [2 ]
Wire, M. B. [3 ]
Aslanis, V. [4 ]
Sallas, W. [5 ]
Zhang, J. [6 ]
Bussel, J. [7 ]
机构
[1] Royal Manchester Childrens Hosp, Manchester, Lancs, England
[2] Ramathibodi Hosp, Bangkok, Thailand
[3] Chimerix, Durham, NC USA
[4] Novartis Pharma AG, Basel, Switzerland
[5] Novartis Pharmaceut, E Hanover, NJ USA
[6] PAREXEL Int, Res Triangle Pk, NC USA
[7] Weill Cornell Med, New York, NY USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
E1420
引用
收藏
页码:588 / 589
页数:2
相关论文
共 2 条
  • [1] Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia
    Wire, Mary B.
    Li, Xiaobin
    Zhang, Jianping
    Sallas, William
    Aslanis, Vassilios
    Ouatas, Taoufik
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (06) : 1199 - 1207
  • [2] Eltrombopag (EPAG) Treatment Improved Platelet Counts in Patients with Persistent or Chronic Immune Thrombocytopenia during a 2-Year, Phase IV, Open-Label Study
    Wong, Raymond S. M.
    Brynes, Russell K.
    Orazi, Attilio
    Aziz, Zeba
    Melikyan, Anait L.
    Salama, Abdulgabar
    Arikan, Ozlem Ocak
    Maier, Joan
    Shamsi, Tahir
    [J]. BLOOD, 2017, 130